National Institute on Drug Abuse HCV Funding

Quick Links:
Charts-View NIH trans-Plan Data
FIC NCI NHLBI NIAID NIDCR NIGMS NIMH NINR	NCCAM NCRR NIAAA NIDA NIDDK NIH NINDS
NIH Acronyms

Sign the Petition- HCV research funding conflicts of interests at NIH
Download - Printer Friendly Version

Contact:
NIH Directors
Institute and Center leaders

Mailing Addresses
for NIH Institutes and Centers

HCV Research

Track Funding

HCV Funded Studies:

HCV Research

HIV Research

Hepatitis B & Viral Hepatitis" Studies

Liver Disease Research

Unknown Category Research

Charts & Data

Treatments

Clinical Trials

Cirrhosis, HCC & Transplant Research

Mental Health

Harm Reduction

Snapshot NIH-TransPlan for HCV Funding

PRESS RELEASE:
Millions of Dollars Redirected HepCop has publicly denounced the National Institutes of Health (NIH) for spending millions of dollars budgeted for Hepatitis C (HCV) on other research agendas.

National Institute on Drug Abuse
NIDA Grants

Total NIDA HCV Funding $18,281,932

NIDA Grants

Description	Project Number	Researcher	Cost	Project Title
Harm Reduction HCV Study	5R01DA023570-02	GARCIA-TSAO, GUADALUPE	$244,622	Stabilize Addiction/Affect, Begin Inmates' Interferon for HCV of Liver (STAABIHL)
$1,575,908	5K23DA018623-05	FLOTTE, TERENCE	$175,986	Pre-Chemotherapeutic Care of HCV Infected Drug Users
	1R01DA021550-01A2	EINAV, SHIRIT	$834,452	HCV Transmission among Young IDUs in NYC
	1K23DA022454-01A1	LIU, HONGJIE	$178,897	Directly Observed Hepatitis C Treatment in Methadone Clinics
	5R01DA016017-06	OTT, MELANIE	$466,965	Acute Hepatitis C Infection in Young Injectors
	5R01DA016159-05	EINAV, SHIRIT	$650,470	Acute HCV Infection in Injection Drug Users
	5R01DA016078-07	STERLING, RICHARD	$712,636	The Progression of Hepatitis C Among IDUs
Harm Reduction HIV/HCV/Alcohol	5R01DA019829-04	SCOTT, JOHN	$706,524	Epidemiology of HIV and Hepatitis C Among Injecting Drug Users in Tijuana
$6,166,877	1R21DA023893-01A1	LO RE, VINCENT	$215,840	Mediation Effect of Network Function on Transition to Injection Drug Use
	5R21DA023399-02	RAISON, CHARLES	$150,780	Reducing HIV Risk Among Methamphetamine IDUs Through Peer Education
	5R01DA020781-03	MASSON, CARMEN	$331,144	Hepatitis Care Coordination in Methadone Treatment
	5K01DA023365-02	HARTGE, PATRICIA	$165,521	Dynamic Modeling of the HCV Epidemic in IDU
	5R01DA022030-03	BROWN, LAWRENCE	$179,626	Electronic Information System to Enhance Practice at an Opioid Treatment Program
	3R01DA019829-03S1	SCOTT, JOHN	$54,773	Epidemiology of HIV and Hepatitis C Among Injecting Drug Users in Tijuana
	5R01DA022177-02	HOWARD, ANDREA	$402,864	Opioids, HIV/HCV and Host Cell Innate Immunity
	5R01DA020841-03	PANDEY, JANARDAN	$354,372	Hepatitis Care Coordination in Methadone Treatment
	1R13DA026294-01	HELLER, THEO	$25,000	Sino-US Symposium in Drug Abuse, HIV and HCV Comorbidity
	2R01DA016065-06A1	SHERMAN, KENNETH	$402,468	HCV Disease Management in HIV- HCV Coinfected IDUs
	1K23DA020383-01A1	SPRATT, HEIDI	$179,212	Buprenorphine as a Bridge to HCV Treatment for HIV/HCV Coinfected Opioid Users
	3R01DA022177-01A1S2	HOWARD, ANDREA	$7,020	Opioids, HIV/HCV and Host Cell Innate Immunity
	5R01DA010164-12	BOURGOIS, PHILIPPE	$360,811	The Logics for HIV Risk Among Homeless Heroin Injectors
	5K01DA017179-05	RAY, RATNA	$169,492	HCV Treatment Cost-Effectiveness in 3 IDU Populations
	5R01DA019383-04	GALE, MICHAEL	$599,233	Staying Safe: Long-Term Injection Drug Users Who Have Avoided HIV & Hepatitis C
	5K23DA022143-03	BRUCE, ROBERT	$174,077	Substance Abuse, HIV and HCV Treatments to Improve Health Outcomes in Drug Users
HCV Based Study	5U19AI040035-13	RAY, RANJIT	$93,054	Cellular Immune Failure in Acute Hepatitis C
$1,792,421	1K23DA023467-01A1	MORASCO, BENJAMIN	$165,533	Chronic Pain and Substance Use in Patients with Hepatitis C
	5R01DA013324-10	STERLING, RICHARD	$643,505	Hepatitis C Pathogenesis & The Human Genome
	5U19AI040035-13	GHANY, MARC	$102,200	Innate Defenses that Control Hepatitis C Virus (HCV)
	5U19AI040035-13	LI, KUI	$65,513	Interferon Signaling and Cellular Permissiveness for Hepatitis C Virus (HCV)
	5R01DA024565-02	RAY, RANJIT	$503,137	Mechanisms of Hepatitis C Virus Evolution
	5K01DA018268-06	BIRK, ALEXANDER	$111,000	SELECTIVE INHIBITION OF HCV TRANSLATION BY TETRAPEPTIDE
	5U19AI040035-13	LAUER, GEORG	$108,479	Virus-Host Interactions in Hepatitis C Virus (HCV) Infections
HIV/HCV Studies	5R01DA011598-10	FREIER, SUSAN	$660,216	Nutritional Status In HIV Hispanic Drug Abusers
$2,432,965	1R01DA022914-01A2	ELHAMMER, AKE	$676,058	Couples-Based HIV/STI Prevention for Injecting Drug Users in Kazakhstan
	1R01DA025932-01	FRIEDMANN, PETER	$372,375	Drug Interactions in Substance Abusers with HIV Infection
	3R01DA023405-02S1	BAUM, MARIANNA	$66,484	HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants
	5R01DA013806-09	STERLING, RICHARD	$499,538	HIV HCV Coinfection Antiviral Therapy and Fibrosis
	3R01DA013806-09S1	STERLING, RICHARD	$100,529	HIV HCV Coinfection Antiviral Therapy and Fibrosis
	5R01DA024563-02	GHANY, MARC	$378,489	INNATE IMMUNE DEFENSE AGAINST HCV and HIV: THE CHIMERIC MOUSE MODEL
	5R01DA019841-09	DASGUPTA, ASIM	$866,282	Natural History of Hepatitis C Infection in HIV Disease
	5R01DA023405-02	BAUM, MARIANNA	$521,643	HIV and HIV/HCV-Infection, Disease Progression, Oxidative Stress and Antioxidants
Interferon/Antivial Treatment HIV/HCV Study	1K01DA024654-01	PFEFFER, LAWRENCE	$180,360	Antiviral Role of APOBEC3 in HIV/HCV Coinfected Patients
Other Treatment Study $2,015,033	1R01DA024549-01A1	GARCIA-TSAO, GUADALUPE	$355,583	Treatment Study Using Depot Naltrexone(2/6)Rhode Island Protocol Treatment Site
	1R01DA024553-01A1	NUNES, EDWARD	$591,774	Treatment Study Using Depot Naltrexone(1/6)Philadelphia Coord/Data Mgmt Site
	1R01DA024555-01A1	LETENDRE, SCOTT	$378,064	Treatment Study Using Depot Naltrexone(3/6)NY/Bellevue Protocol Treatment Site
	1R01DA024550-01A1	KOZIEL, MARGARET	$309,076	Treatment Study Using Depot Naltrexone(5/6)Baltimore Protocol Treatment Site
	1R01DA024554-01A1	NORTH, CAROL	$380,536	Treatment Studies Using Depot Naltrexone (4/6) Columbia Protocol Treatment Site
Unknown	5P30DA015625-07	KHAKOO, SALIM	$148,050	Administrative Core
$2,409,719	5P01DA012065-09	LI, KUI	$127,943	BIOMARKERS
	5U19AI040035-13	STERLING, RICHARD	$95,837	Clinical Core
	5P30DA015625-07	KHAKOO, SALIM	$741,080	FUNCTIONAL GENOMICS & VIROLOGY CORE
	5P01DA012065-09	MASLIAH, ELIEZER	$270,908	NEUROBIOLOGY
	5P01DA012065-09	HERMANN, THOMAS	$355,741	NEUROCOGNITIVE
	5P01DA012065-09	CALIGIURI, MICHAEL	$14,761	NEUROMOTOR
	5P30DA015625-07	SARNOW, PETER	$655,399	PROTEOMICS CORE
	Total NIDA Funding		$18,281,932

Who's ACUTE and Who's NOT? HIV/AIDS- CDC Data Includes Both Acute (less than 6 months) and Chronic HIV Infections
2007	2006	2005	2004	2003	2002	2001
35,962	35,695	36,127	37,633	38,893	N/A	N/A

HCV- CDC Data Includes HCV Acute Infections Only
2007	2006	2005	2004	2003	2002	2001
N/A	19,000	21,000	26,000	28,000	29,000	24,000

http://www.cdc.gov/HIV

In 1994, the CDC could not deny the failure of public health to report HCV infections. Eighty-five percent reported increases in the number of cases reported during the past 5 years. But it was discovered, because of the failure to report "acute" HCV infection, the data could only identify a true 12% increase in the disease incidence. 1

Despite the flawed data the figures were used by NIDA to support a super-sized hepatitis C epidemic by injected drug users. Recent and very large urban health studies report actual drug related transmissions occurs 1/3 the rate NIDA projects. Political verses scientific knowledge is alive and well at NIDA. 2

Scientists also raised questions concerning research integrity, during hearings held by a Committee on Government Reform and Oversight. Reports in subcommittee files from Department of Health and Human Services make noteworthy that the National Institute on Drug Abuse [NIDA] spent the most NIH resources and continues to spend the most resources on HCV research. Stating it may reflect an institutional bias within HHS that HCV is a disease of injection drug users. This bias may have worked against early recognition of HCV as a broader public health problem. 3

1. Source: Is the recent increase in the reported cases of hepatitis C / NANB a real increase? Am J Infect Control. 1996 Oct;24(5):415-6
Source: David Bernstein, MD reported the discrepancies at the 2004 55th Annual Meeting of the American Association for the Study of Liver Diseases

2. Source: Seroprevalence of Hepatitis C Virus and Hepatitis B Virus Among San Francisco Injection Drug Users, 1998-2000." Tseng et al. Hepatology; September 2007; (DOI: 10.1002/hep.21765). Received: 21 July 2006; Accepted: 9 April 2007 Digital Object Identifier (DOI) 10.1002/hep.21765

3. Source: House Report 105 HR 820 Seventh Report By The Committee On Government Reform And Oversight 51 351 CC Union Calendar No. 461 105th Congress, 2d Session

Source: National Institutes of Health Research Portfolio Online Reporting Tool (RePORT) Reports,
Data and Analyses of NIH Research Activities
Retrieved on March 18, 2009
http://report.nih.gov/rcdc/categories/ProjectSearch.aspx?FY=2008&DCat=Hepatitis+-+C

Permission is granted to use all information from this website in pursuit of ending NIH's "Trans-Plan" discriminatory practices against HCV research funding allocations. Please Credit: HCVets.com Educational Website & Support Forums for Military Related HCV Exposures.

Contact HepCop
Email: Staff